MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease

    N. Miyaue, M. Nomoto, H. Yabe, Y. Yamanishi, S. Tada, R. Ando, M. Kubo, M. Nagai (Ehime, Japan)

    Objective: The aim of this study is to evaluate the pharmacokinetics of levodopa in patients with Parkinson’s disease (PD) who underwent gastrointestinal surgery. Background: Levodopa…
  • 2019 International Congress

    Behavioural aspect of transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by Ropinirole alginate nanocomposite

    F. Naz, R. X, YHS. Siddique (Aligarh, India)

    Objective: To evaluate the behavioural changes in transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by different doses of Ropinirole alginate nanocomposite (RANC).…
  • 2019 International Congress

    Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease

    S. Neo, A. Wong, HL. Ng, W. Li, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)

    Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…
  • 2019 International Congress

    Results of community pharmacist-led structured medication reviews in Parkinson’s Disease

    N. Oonk, P. Oude Avenhuis, K. Movig, K. Koehorst-Ter Huurne, WH. Nijmeijer, M. van Kesteren-Biegstraaten, J. Vd Palen, L. Dorresteijn (Enschede, Netherlands)

    Objective: To obtain insight in the process of community pharmacist-led structured medication reviews in patients with Parkinson’s disease (PD), by evaluating medication modifications and recommendations, and…
  • 2019 International Congress

    Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats

    CA. Pisanò, A. Brugnoli, S. Novello, C. Caccia, C. Keywood, E. Melloni, G. Padoani, S. Vailati, M. Morari (Ferrara, Italy)

    Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…
  • 2019 International Congress

    Effect of dopamine D2-receptor antagonist and basal ganglia neuromodulation on neuronal activity in the cerebral motor area and cerebellar dentate nucleus

    K. Schwabe, A. Abdulbaki, S. Helgers, J. Krauss, M. Alam (Hannover, Germany)

    Objective: The effect of the D2-antagonist haloperidol on single unit activity (SU) and local field potentials (LFPs) of the cerebellar dentate nucleus and motor cortex…
  • 2019 International Congress

    Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

    M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

    Objective: To investigate the effects of safinamide (saf) on synaptic plasticity of spiny projection neurons (SPNs) and the antiparkinsonian effect in dopamine (DA) denervated rats…
  • 2019 International Congress

    Chlorogenic acid attenuates the MPTP induced apoptosis in Parkinson’s disease mouse model through pAkt signaling pathway

    S. Singh, S. Singh (Varanasi, India)

    Objective: This study deals to investigate and explore the anti-apoptotic and molecular mechanisms of CGA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinsonian mice model. Background: The debilitating…
  • 2019 International Congress

    Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study

    I. Straka, M. Minár, M. škorvánek, M. Grofik, J. Benetin, P. Valkovič (Bratislava, Slovakia)

    Objective: To find out whether pill box organizers with alarm would improve the rate of adherence in non-adherent patients with Parkinson’s disease (PD) taking three…
  • 2019 International Congress

    Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

    K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

    Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…
  • « Previous Page
  • 1
  • …
  • 1227
  • 1228
  • 1229
  • 1230
  • 1231
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley